2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
307
Lung Neoplasms
111
Pancreatic Neoplasms
70
Neoplasms
56
Neoplasm Metastasis
32
Brain Neoplasms
31
Head and Neck Neoplasms
26
Squamous Cell Carcinoma of Head and Neck
25
Breast Neoplasms
25
Glioblastoma
24
Adenocarcinoma of Lung
23
Gliosarcoma
22
Non-Squamous Non-Small Cell Lung Cancer
21
Colorectal Neoplasms
18
Carcinoma, Hepatocellular
17
Adenocarcinoma, Bronchiolo-Alveolar
16
Rectal Neoplasms
13
Colonic Neoplasms
13
Carcinoma, Renal Cell
13
Glioma
12
Esophageal Neoplasms
11
Astrocytoma
11
Central Nervous System Neoplasms
9
Carcinoma, Squamous Cell
9
Salivary Gland Neoplasms
8
Prostatic Neoplasms
8
Oligodendroglioma
8
Gallbladder Neoplasms
8
Adenocarcinoma
8
Ovarian Neoplasms
7
Interventions
dacetuzumab
2
Bortezomib
2
sonidegib
1
ruxolitinib
1
ficlatuzumab
1
Vorinostat
1
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
1
Lenalidomide
1
Erlotinib Hydrochloride
1
Dexamethasone
1
Calcium Dobesilate
1
ARQ531
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemorrhagic Disorders
×
Erlotinib Hydrochloride
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled